RT Journal Article
SR Electronic
T1 EPV120/#399 Endometrial cancer: molecular analysis and clinicopathological correlation: a pilot study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A77
OP A78
DO 10.1136/ijgc-2021-IGCS.190
VO 31
IS Suppl 4
A1 Dahiya, A
A1 Thomas, A
A1 Pai, R
A1 Daniel, S
A1 Sebastian, A
A1 Susan Thomas, D
A1 Thomas, V
A1 Chandy, R
A1 Samuel Ram, T
A1 S, A
A1 Rebekah, G
A1 Peedicayil, A
YR 2021
UL http://ijgc.bmj.com/content/31/Suppl_4/A77.3.abstract
AB Objectives Aim/Introduction: Limited reproducibility and imprecise risk estimation of traditional classification have paved the way for molecular research in endometrial cancer. The study aims to determine the prevalence of Polymerase Epsilon gene (POLE) mutation, P53 mutations, and microsatellite instability (MSI) in endometrial cancer, followed by clinicopathological correlation.Methods Materials and Methods: A retrospective cohort involving 50 consecutive patients of primary endometrial carcinoma was identified from 01.01.2016 to 01.02.2018 using the computerized database. Molecular classification of endometrial cancer was done with the following components. POLE ultramutated: using exon 9–14 mutational analysis, Microsatellite instability (MSI) using Mismatch repair protein IHC (MLH1, MSH2, MSH6), and Copy number high/low: using p53 IHC as a surrogate marker.Results Results/Conclusions An interim analysis of 29 patients was done. Eight (27.6%) patients had MLH1 mutation, 1(3.5%) patient had POLE and MLH1 mutation, while 2 (6.9%) had both POLE and P53 mutation. Seven (24.2%) patients were found to have null mutations of P53, while the remaining 11 (37.9%) had no specific molecular profile (NSMP). ESMO-ESGO risk group correlation, recurrences, and deaths are shown in table 1.View this table:Abstract EPV120/#399 Table 1 Baseline characteristics of molecular supgroupsConclusions Implications: Recurrence in low risk groups, behaviour of multiple classifiers, NSMP group and POLE mutated higher risk/stage cancers are areas still under-researched. A larger study exploring the integrated approach will help answer these questions and open novel avenue of research aimed at immunotherapy in endometrial cancer especially in recurrent settings.